[{"address1": "2051 Ringwood Avenue", "city": "San Jose", "state": "CA", "zip": "95131", "country": "United States", "phone": "408 457 3700", "website": "https://www.ranitherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.", "fullTimeEmployees": 140, "maxAge": 86400, "priceHint": 4, "previousClose": 4.0, "open": 4.07, "dayLow": 4.0, "dayHigh": 4.2, "regularMarketPreviousClose": 4.0, "regularMarketOpen": 4.07, "regularMarketDayLow": 4.0, "regularMarketDayHigh": 4.2, "beta": 0.258, "forwardPE": -5.5333333, "volume": 134100, "regularMarketVolume": 134100, "averageVolume": 150458, "averageVolume10days": 64590, "averageDailyVolume10Day": 64590, "marketCap": 214480304, "fiftyTwoWeekLow": 1.82, "fiftyTwoWeekHigh": 8.75, "fiftyDayAverage": 5.5608, "twoHundredDayAverage": 3.582425, "currency": "USD", "enterpriseValue": 112127064, "floatShares": 12709504, "sharesOutstanding": 26303900, "sharesShort": 871213, "sharesShortPriorMonth": 1715777, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.033099998, "heldPercentInsiders": 0.48880002, "heldPercentInstitutions": 0.13966, "shortRatio": 3.49, "shortPercentOfFloat": 0.066300005, "impliedSharesOutstanding": 51682000, "bookValue": 0.281, "priceToBook": 14.768684, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -33081000, "trailingEps": -1.29, "forwardEps": -0.75, "pegRatio": 0.42, "enterpriseToEbitda": -1.787, "52WeekChange": -0.028103054, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "RANI", "underlyingSymbol": "RANI", "shortName": "Rani Therapeutics Holdings, Inc", "longName": "Rani Therapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5ed5bf18-2fc9-357f-8d44-03f1c0fe19bf", "messageBoardId": "finmb_242425883", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.15, "targetHighPrice": 15.0, "targetLowPrice": 8.0, "targetMeanPrice": 11.13, "targetMedianPrice": 11.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 39581000, "totalCashPerShare": 1.505, "ebitda": -62735000, "totalDebt": 35410000, "quickRatio": 2.972, "currentRatio": 3.095, "debtToEquity": 243.619, "returnOnAssets": -0.53029, "returnOnEquity": -1.72955, "freeCashflow": -24633124, "operatingCashflow": -48484000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]